A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects

Trial Profile

A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Andexanet alfa (Primary) ; Apixaban; Edoxaban; Enoxaparin sodium; Rivaroxaban
  • Indications Haemorrhage
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 22 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top